JP2022023223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022023223A5 JP2022023223A5 JP2021182945A JP2021182945A JP2022023223A5 JP 2022023223 A5 JP2022023223 A5 JP 2022023223A5 JP 2021182945 A JP2021182945 A JP 2021182945A JP 2021182945 A JP2021182945 A JP 2021182945A JP 2022023223 A5 JP2022023223 A5 JP 2022023223A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- ngf antibody
- human ngf
- antibody fab
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016061353 | 2016-03-25 | ||
| JP2016061353 | 2016-03-25 | ||
| JP2018507426A JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| PCT/JP2017/011910 WO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ'フラグメント含有医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507426A Division JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022023223A JP2022023223A (ja) | 2022-02-07 |
| JP2022023223A5 true JP2022023223A5 (enExample) | 2022-12-16 |
| JP7215555B2 JP7215555B2 (ja) | 2023-01-31 |
Family
ID=59900467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507426A Pending JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| JP2021182945A Active JP7215555B2 (ja) | 2016-03-25 | 2021-11-10 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507426A Pending JPWO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200299371A1 (enExample) |
| EP (1) | EP3434283A4 (enExample) |
| JP (2) | JPWO2017164349A1 (enExample) |
| KR (1) | KR20180123559A (enExample) |
| CN (1) | CN108883177A (enExample) |
| CA (1) | CA3018473A1 (enExample) |
| MX (1) | MX2018011675A (enExample) |
| PH (1) | PH12018501978A1 (enExample) |
| RU (1) | RU2018137495A (enExample) |
| SG (1) | SG11201808119UA (enExample) |
| TW (1) | TW201738269A (enExample) |
| WO (1) | WO2017164349A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
| CN117752825A (zh) * | 2018-10-10 | 2024-03-26 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
| CN121079108A (zh) * | 2023-05-12 | 2025-12-05 | 五稜化药株式会社 | 冻结干燥制剂、冻结干燥溶液和这些的制造方法、以及液剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277828B1 (en) | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| US20070184050A1 (en) * | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
| JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| TR201802935T4 (tr) | 2008-09-19 | 2018-03-21 | Pfizer | Stabil sıvı antikor formülasyonu. |
| NZ602054A (en) * | 2010-03-17 | 2014-10-31 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
| KR101999867B1 (ko) * | 2011-08-11 | 2019-07-12 | 아스텔라스세이야쿠 가부시키가이샤 | 신규 항 인간 ngf 항체 |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
-
2017
- 2017-03-24 CN CN201780019929.0A patent/CN108883177A/zh active Pending
- 2017-03-24 RU RU2018137495A patent/RU2018137495A/ru unknown
- 2017-03-24 US US16/087,908 patent/US20200299371A1/en not_active Abandoned
- 2017-03-24 SG SG11201808119UA patent/SG11201808119UA/en unknown
- 2017-03-24 EP EP17770389.9A patent/EP3434283A4/en not_active Ceased
- 2017-03-24 CA CA3018473A patent/CA3018473A1/en not_active Abandoned
- 2017-03-24 MX MX2018011675A patent/MX2018011675A/es unknown
- 2017-03-24 WO PCT/JP2017/011910 patent/WO2017164349A1/ja not_active Ceased
- 2017-03-24 JP JP2018507426A patent/JPWO2017164349A1/ja active Pending
- 2017-03-24 TW TW106109999A patent/TW201738269A/zh unknown
- 2017-03-24 KR KR1020187030401A patent/KR20180123559A/ko not_active Ceased
-
2018
- 2018-09-13 PH PH12018501978A patent/PH12018501978A1/en unknown
-
2021
- 2021-11-10 JP JP2021182945A patent/JP7215555B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022023223A5 (enExample) | ||
| JP2024099682A5 (enExample) | ||
| ES2338218T3 (es) | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. | |
| RU2519031C1 (ru) | Жидкие препаративные формы для длительно действующего конъюгата g-csf | |
| JP5946448B2 (ja) | 持続型ヒト成長ホルモン結合体液状製剤 | |
| TWI738632B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| RU2600847C2 (ru) | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина | |
| ES2700925T3 (es) | Formulaciones líquidas para conjugado de eritropoyetina de acción prolongada | |
| TWI494120B (zh) | 長效α－型干擾素接合物之液體調配物 | |
| ES2734076T3 (es) | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada | |
| JP2021503485A5 (enExample) | ||
| FI3576788T3 (fi) | Matalan ph-arvon omaava farmaseuttinen koostumus, joka käsittää t-soluihin sitoutuvia vasta-ainekonstrukteja | |
| KR20220024914A (ko) | 분지형 링커를 사용한 세포독성제 대 세포 결합 분자의 접합체 | |
| TWI848956B (zh) | 包含vegf拮抗物之液體組成物 | |
| JP2022174082A5 (enExample) | ||
| JP2022523103A (ja) | 分岐連結体とアマニタトキシンとの共役体 | |
| CN101312744A (zh) | 免疫球蛋白融合蛋白制剂 | |
| JP2021503485A (ja) | ＶＥＧＦＲ−Ｆｃ融合タンパク質製剤 | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP2018115166A (ja) | 持続型ヒト成長ホルモン結合体の高濃度液剤 | |
| JP7215555B2 (ja) | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 | |
| CN113645953B (zh) | 制剂 | |
| CN107073080A (zh) | 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂 | |
| CN112312890A (zh) | 稳定的杂合fc融合g-csf制剂 | |
| TWI775827B (zh) | 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法 |